Wang J, Hu Y, Wu Z, Xiao L, et al.; Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma; Biology of Blood and Marrow Transplantation 25, 6 (2019).
J Yu, Y Hu, C Pu, L Xiao, Z Wu, H Huang, et al.; Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient; Bone Marrow Transplant 52, 1065–1067 (2017). (ICT was listed as co-corresponding author.)
Hu Y, Wang J, Pu C, Xiao L, Wu Z, Huang H, et al.; Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Res Treat. (2018). (ICT was listed as co-corresponding author.)
Wang, X., Hu, Y., Xiao L., Wu Z., et al.; Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. Bone Marrow Transplant 54, 2072–2080 (2019).
Hu, Y., Wang, J., Xiao, L., Wu, Z., et al.; A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Bone Marrow Transplant 54, 1208–1217 (2019).
Yuhong Chen, Yifei Cheng, Lei Xiao, et al.; Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukemia with no response to donor lymphocyte infusions after haploidentical hematopoietic stem cell transplantation; Br J Haematol, 179 (2018).
Yongxian Hu, Zhao Wu, Chengfei Pu, Lei Xiao, et al.; Potent Anti-leukemia Activities of Chimeric Antigen Receptor–ModiﬁedTCellsagainstCD19in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia; Clin Cancer Res; July 1, 2017 (23) (13) 3297-3306. (ICT was listed as co-corresponding author.)
Yongxian Hu, Jie Sun, Zhao Wu, Chengfei Pu, Lei Xiao, et al.; Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy; J Hematol Oncol 9, 70 (2016).